Navigation Links
Inovio Pharmaceuticals Completes PENNVAX™-B HIV Vaccine Phase I Study, Demonstrates Best-in-Class T-Cell Immune Responses
Date:9/14/2011

AX™-B vaccine, and 30 subjects received a 3 mg dose of PENNVAX™-B along with 1 mg of GENEVAX™IL-12 DNA. All volunteers received vaccine or placebo administered via intramuscular injection with electroporation at months 0, 1, and 3. The T-cell immune responses were detected using a validated flow cytometry-based intracellular cytokine staining (ICS) assay at the HVTN core immunology laboratory at the Fred Hutchinson Cancer Research Center (Seattle, WA).

These data indicate that antigen-specific T-cell responses were generated by the vaccine in a majority of subjects. Overall, either CD4+ or CD8+ or both T-cell responses were observed against at least one of the vaccine antigens in 83.3% (30 of 36) of evaluated subjects after three vaccinations using electroporation. The response rate increased to 88.9% (24 of 27) of evaluated subjects after three vaccinations with electroporation plus the IL-12 cytokine gene adjuvant. The investigators in this study concluded that PENNVAX™-B + IL-12 plasmid delivered via electroporation led to frequencies and magnitudes of cellular immune responses equal to or greater than those reported from current vector-based HIV vaccines such as adenovirus or traditional DNA vaccination without electroporation. Further trials delivering an HIV DNA vaccine using electroporation with or without IL-12 as a vaccine strategy are merited.

Specifically, after three vaccinations with the PENNVAX™-B vaccine given with IL-12 and electroporation:

  • Antigen-specific CD4+ T-cell responses were generated by the vaccine in 80.8% of evaluated vaccine recipients (21 of 26).
  • Significantly strong antigen-specific, CD8+ T-cell responses were also generated by the vaccine in 51.9% of evaluated vaccine recipients (14 of 27).
  • In an assessment of immune response durability out to six months post dose 3, 53.6% (15 of 28) of the subjects maintained positive CD4+ T-cell responses and 42.9% (12 of 28) of
    '/>"/>

  • SOURCE Inovio Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Inovio Pharmaceuticals Adds Two Medical Innovators to Its Scientific Advisory Board
    2. Inovio Pharmaceuticals to Present at Investor Conferences
    3. Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results
    4. Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I
    5. Inovio Pharmaceuticals Announces Transition of Avtar Dhillon to Non-Executive Chairman of the Board
    6. Inovio Pharmaceuticals to Present at Scientific & Industry Conferences
    7. Inovio Pharmaceuticals Subsidiary, VGX Animal Health, to Present at VetHealth Global 2011, June 14-17, 2011
    8. Inovio Pharmaceuticals to Present at American Society of Gene & Cell Therapy Annual Meeting May 18 - 21, 2011
    9. Inovio Pharmaceuticals Market-Leading Intellectual Property Recognized by MDB Capital Award
    10. Inovio Pharmaceuticals to Present at Investor Conferences
    11. Inovio Pharmaceuticals, Transgene and ChronTech Pharma to Collaborate on Heterologous Prime-Boost Therapeutic Vaccination Against Hepatitis C
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/24/2014)... , Nov. 24, 2014 Luoxis ... (NYSE MKT: AMPE), today announced the presentation of ... Diagnostic System as a broadly applicable and robust ... in the body in response to injury, illness, ... performed in collaboration with Luoxis, academic and pharmaceutical ...
    (Date:11/24/2014)... Nov. 24, 2014 The Female Health Company ... investor conference call to discuss its operating results for ... 2014 on Tuesday, December 2, 2014 at 11:00 a.m. ... its operating results earlier the same day. ... conference call by dialing 1-877-374-8416 (international participants dial 1-412-317-6716) ...
    (Date:11/24/2014)... , Nov. 24, 2014  GlySens Incorporated announced ... million dollar grant from the National Institute of Diabetes ... the National Institutes of Health (NIH).  The grant is ... second generation ICGM™ long term implantable glucose monitoring system.  ... and enrollment is expected to begin before the end ...
    Breaking Medicine Technology:Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 2Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 3Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 4Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 5The Female Health Company To Report FY2014 Operating Results on Tuesday, December 2, 2014 2GlySens Incorporated Awarded $2 Million Grant from the National Institutes of Health 2
    ... with Durezol Dosed Prior to Surgery, TAMPA, ... held ophthalmic-focused biopharmaceutical company, announced,today that Durezol(TM) (difluprednate ... was approved by the U.S. Food and,Drug Administration ... for the treatment of inflammation and pain associated ...
    ... MEETING, Pa., Oct. 6 Genaera,Corporation (Nasdaq: GENR ... trial of trodusquemine (MSI-1436), Genaera,s lead drug candidate,for the ... a novel,inhibitor of PTP1B, a validated molecular target that ... to normalize glucose and decrease,appetite. In the study, MSI-1436 ...
    Cached Medicine Technology:Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 2Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 3Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 4Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 5Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 2Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 3Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 4
    (Date:11/24/2014)... November 24, 2014 Mental health ... day. They break up families, ruin careers, and ... hope for those that suffer,” says Hardy ... is showing that our specialized nutritional treatments can ... appear on “Mind Over Matter”, the premiere episode ...
    (Date:11/24/2014)... Gersowitz Libo & Korek, P.C., a leading national ... recognition in the 2015 Edition of U.S. News-Best Lawyers list ... unique combination of quality law practice and breadth of legal ... and especially grateful to our clients whose continued support of ... said Jeff S. Korek, senior partner at Gersowitz Libo ...
    (Date:11/23/2014)... a well-known wedding dress manufacturer, has unveiled its new collection ... now offered at deeply discounted prices, up to 75 percent ... 15. The main purpose of the promotion is to expand ... are ideal options for ladies who are eager to look ... new mint cocktail dresses are very beautiful; they are made ...
    (Date:11/23/2014)... Pro Ace Care, a renowned Vancouver hot water ... providing an 8 year warranty on its selected hot water ... up due to the impending winter season, it was important ... premium service that the company provides. As a result, Pro ... Wood and Bradford hot water tanks. , “Every installer ...
    (Date:11/23/2014)... Locks-Magnetic.com, a notable magnetic locks maker, has released ... products are available at low rates up to 30% ... the new emergency doors. The emergency door adopts fireproof ... from several colors. All of the products are top-quality ... is not as easy as many people think. ...
    Breaking Medicine News(10 mins):Health News:Nutritional Mental Health Treatment Featured on Access Health Airing on Lifetime Television® 2Health News:Nutritional Mental Health Treatment Featured on Access Health Airing on Lifetime Television® 3Health News:U.S. News-Best Lawyers “Best Law Firms” Names Gersowitz Libo & Korek P.C. a 2015 Tier 1 Ranking Firm 2Health News:Trendy Long Black Evening Gowns Now Provided By iFitDress.com 2Health News:Pro Ace Care Now Gives 8 Year Guarantee on Selected Vancouver Hot Water Tanks 2
    ... its patient care and billing like Tesco and Toyota to ... be improved by regularizing the movement of patients from Accident ... ,Services like redesigning, making improvements in healthcare, and giving ... Toyota group of companies, which needs to be copied by ...
    ... has stated, that it suspects that ‘Pneumonic plague’ is responsible ... according to preliminary test results// that it has conducted. The ... set up to treat patients. They also explained that the ... lack of security ,in the area. ,The outbreak ...
    ... of postgraduate students at Tshwane University of Technology (TUT) ... inch//. No, this is not revenge on your husband ... method to fight obesity. ,Department of sport ... Andrew McKune said that the group of 40 students ...
    ... resorted to the strike against OBC reservation in educational institutions, ... // to doctors for the strike period was not a ... no pay. If court orders to release the salaries, we ... to protests by medicos at the AIIMS for not getting ...
    ... Peace, Vijay Amritraj, has launched a charity that will ... ,The UN estimates that about 5.5 million ... a fraction is getting treatment despite the country's pharmaceutical ... ,Launching the `Amritraj Foundation' yesterday, the 53-year old sportsman, ...
    ... today said it has allotted 61,716 equity shares upon conversion ... FCCB holders. // ,The committee of directors at ... five each of the company at a premium of Rs ... each, the company informed the Bombay Stock Exchange., ,Consequently, ...
    Cached Medicine News:
    The Calcitonin ELISA is intended for the quantitative determination of Calcitonin in human serum....
    ... exclusively distributed by Medtronic, sets the ... intra-operative imaging with surgical navigation in ... is one of the most comprehensive ... Exceptional image quality from a low-field ...
    Microwell EIA for detection of Calcitonin...
    Mircrowell EIA for detection of Intact PTH...
    Medicine Products: